Sanofi Halts the P-III (CARMEN-LC03) Trial of Tusamitamab Ravtansine for Non-Squamous Non-Small Cell Lung Cancer
Shots:
- Sanofi will halt the P-III clinical trial (CARMEN-LC03) assessing tusamitamab ravtansine alone vs docetaxel in previously treated patients with metastatic non-squamous (NSq) NSCLC exhibiting elevated levels of CEACAM5
- The trial terminated because tusamitamab ravtansine did not show improvement in PFS at the final analysis as evaluated by the Independent Data Monitoring Committee (IDMC) vs docetaxel. Although there was an improvement in OS
- Tusamitamab ravtansine demonstrated similar safety profile with a lower incidence of significant AEs across various clinical categories
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi Announces the Result of Sarclisa (isatuximab)+ KRd in P-III Trial to Treat Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
